US2022105075A1PendingUtilityA1

Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents

70
Assignee: INTEGURX THERAPEUTICS LLCPriority: Aug 24, 2012Filed: Aug 16, 2021Published: Apr 7, 2022
Est. expiryAug 24, 2032(~6.1 yrs left)· nominal 20-yr term from priority
Inventors:Kirti H. ValiaAgis Kydonieus
A61K 31/46A61K 31/4178A61P 43/00A61K 31/4709A61P 25/24A61P 17/00A61K 9/08A61K 47/12A61K 31/439A61P 25/16A61K 9/7023A61K 9/0014A61P 25/28A61P 1/08A61P 25/04A61P 25/06
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present application discloses chemical compositions and methods for enhancing the transdermal permeation of therapeutic agents through skin. The chemical compositions and methods of the invention can include combinations of a first fatty acid having about 14 or more carbon atoms and a second fatty acid having about 10 or less carbon atoms. These compositions are useful for the delivery of therapeutic agents, in particular hard to deliver drugs such as those that have fused rings, including ondansetron, and large drugs such as peptides. The compositions of the invention can be formulated as transdermal gels, lotions, creams, transdermal patches, sprays or mists.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition comprising an anti-coagulant, oleic acid, and levulinic acid. 
     
     
         2 . The composition of  claim 1 , comprising about 0.1% to about 30%, by weight of the composition, of the oleic acid. 
     
     
         3 . The composition of  claim 1 , comprising about 2.5% to about 7.5%, by weight of the composition, of the oleic acid. 
     
     
         4 . The composition of  claim 1 , comprising about 1% to about 5%, by weight of the composition, of the oleic acid. 
     
     
         5 . The composition of  claim 1 , comprising about 0.1% to about 30%, by weight of the composition, of the levulinic acid. 
     
     
         6 . The composition of  claim 1 , comprising about 1% to about 5%, by weight of the composition, of the levulinic acid. 
     
     
         7 . The composition of  claim 1 , comprising about 0.5% to about 2.5%, by weight of the composition, of the levulinic acid. 
     
     
         8 . The composition of  claim 1 , that is for use on human skin. 
     
     
         9 . A transdermal patch comprising a composition comprising an anti-coagulant, oleic acid, and levulinic acid. 
     
     
         10 . The transdermal patch of  claim 9 , comprising about 0.1% to about 30%, by weight of the composition, of the oleic acid. 
     
     
         11 . The transdermal patch of  claim 9 , comprising about 2.5% to about 7.5%, by weight of the composition, of the oleic acid. 
     
     
         12 . The transdermal patch of  claim 9 , comprising about 1% to about 5%, by weight of the composition, of the oleic acid. 
     
     
         13 . The transdermal patch of  claim 9 , comprising about 0.1% to about 30%, by weight of the composition, of the levulinic acid. 
     
     
         14 . The transdermal patch of  claim 9 , comprising about 1% to about 5%, by weight of the composition, of the levulinic acid. 
     
     
         15 . The transdermal patch of  claim 9 , comprising about 0.5% to about 2.5%, by weight of the composition, of the levulinic acid. 
     
     
         16 . The transdermal patch of  claim 9 , that is for use on human skin.

Join the waitlist — get patent alerts

Track US2022105075A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.